Loading
A phase 2 trial of Gotistobart, Pembrolizumab in ovarian cancer, run by OncoC4, Inc., active and no longer recruiting.
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer is a phase 2 interventional study registered as NCT05446298 by OncoC4, Inc., with 58 participants enrolled, started 2022-12-22 and due to reach its primary completion in 2026-08-30. Interventions recorded: ONC-392, Pembrolizumab. Conditions listed: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares OncoC4, Gotistobart, Pembrolizumab, Immune checkpoint inhibitors.
Shares OncoC4, Gotistobart.
Shares OncoC4, Gotistobart.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/